#6 - AstraZeneca (NASDAQ:AZN)
Biopharmaceutical giant AstraZeneca PLC (NASDAQ: AZN) is a steady performer in what can be a volatile sector. In addition to its active drug portfolio, which includes treatments for oncology and rare diseases, the company's pipeline includes over 190 drug candidates.
Of course, not all of those drugs will make it through the clinical trial stage, but AstraZeneca projects at least 20 new medicine launches by 2030. The company anticipates its revenue to reach approximately $80 billion by then—nearly doubling its current annual revenue.
AZN stock has a forward P/E ratio of 16.1, which is in line with the sector average. And with a dividend that yields over 2%, AstraZeneca displays many of the characteristics that patient investors look for in a slow-and-steady stock: a solid mix of stability, growth potential, and reliable income.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
More about AstraZeneca- Current Price
- $76.21
- Consensus Rating
- Buy
- Ratings Breakdown
- 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $89.75 (17.8% Upside)
